Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA-Mutated Ovarian Carcinoma”

73 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 73 results

Not applicableStudy completedNCT03471572
What this trial is testing

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

Who this might be right for
Ovarian Cancer
AstraZeneca 240
Not applicableLooking for participantsNCT06588322
What this trial is testing

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

Who this might be right for
Ovarian Cancer
Institut Claudius Regaud 130
Not applicableLooking for participantsNCT07498829
What this trial is testing

Population Based Germline Testing for Early Detection and Prevention of Cancer

Who this might be right for
Breast Cancer RiskOvarian Cancer RiskCancer Gene Mutation
Queen Mary University of London 6,000
Large-scale testing (Phase 3)Active Not RecruitingNCT01844986
What this trial is testing

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Who this might be right for
Newly DiagnosedAdvanced Ovarian CancerFIGO Stage III-IV+4 more
AstraZeneca 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Early research (Phase 1)Not Yet RecruitingNCT07088588
What this trial is testing

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Not applicableStudy completedNCT03470402
What this trial is testing

Decision Support for BRCA Testing in Ethnically Diverse Women

Who this might be right for
Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
Columbia University 276
Not applicableNot Yet RecruitingNCT06393543
What this trial is testing

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis

Who this might be right for
BRCA MutationSerous Tubal Intraepithelial CarcinomaOvarian Carcinoma+1 more
Radboud University Medical Center 600
Early research (Phase 1)UnknownNCT02225015
What this trial is testing

Cancer Prevention in Women With a BRCA Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationBreast Cancer+1 more
Women's College Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT06395519
What this trial is testing

PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more
858 Therapeutics, Inc. 120
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Early research (Phase 1)UnknownNCT02950064
What this trial is testing

Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Who this might be right for
Pancreatic NeoplasmsOvarian NeoplasmsBreast Neoplasms+1 more
Placon Therapeutics 95
Large-scale testing (Phase 3)Active Not RecruitingNCT01874353
What this trial is testing

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Platinum SensitiveBRCA MutatedRelapsed Ovarian Cancer+1 more
AstraZeneca 327
Testing effectiveness (Phase 2)Study completedNCT01472783
What this trial is testing

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Who this might be right for
Recurrent, Epithelial Ovarian Cancer
Vejle Hospital 49
Not applicableActive Not RecruitingNCT06497270
What this trial is testing

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial

Who this might be right for
BRCA MutationEstrogen DeficiencySurgical Menopause+3 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 3
Large-scale testing (Phase 3)Study completedNCT02903004
What this trial is testing

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

Who this might be right for
Ovarian Neoplasms
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 242
Testing effectiveness (Phase 2)Enrolling By InvitationNCT04361370
What this trial is testing

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
Yonsei University 44
Load More Results